Pharmaron Beijing Co Ltd (Pharmaron) is a life science service company that provides drug research and development services in the areas of chemistry, biology, pharmacology, DMPK, toxicology and chemical development. The company's service offerings include synthetic, medicinal and analytical chemistry, biology, pharmacology, drug safety assessment, radiochemistry and isotopically labeled metabolism, chemical and pharmaceutical development and clinical development services. Pharmaron serves small and large biotechnology and pharmaceutical companies. The company operates chemical manufacturing, drug R&D, radiolabelled chemistry and metabolism and clinical research facilities in the US, the UK, China and Hong Kong. Pharmaron is headquartered in Beijing, China.
Headquarters
China
Address
No. 6 Taihe Road, Beijing Economic And T, 100176
Website
www.pharmaron.cn
Telephone
86 10 57330087
No of Employees
19,481
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
300759 (SHE)
Revenue (2022)
$1.6B
12.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
16.5%
(2022 vs 2021)
Market Cap*
$4.1B
Net Profit Margin (2022)
XYZ
3.7%
(2022 vs 2021)
* As of and is in US$
Pharmaron Beijing Co Ltd premium industry data and analytics
Products and Services
| Services |
|---|
| Laboratory Chemistry Services |
| Biosciences |
| Chemistry, Manufacturing and Control Services |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Plans/Strategy | In October, Pharmaron Chemicals plans to invest US$10.5 million in Rxilient Biohub Pte. Ltd. with China Medical System, Rxilient Health Pte. Ltd and Healthy Goal Limited to expand pharmaceutical CDMO service capabilities in Southeast Asia. |
| 2023 | Financing Agreements | In March, the company announced that Gene Therapy CDMO secured a grant from the UK Government’s Life Sciences Innovation Manufacturing Fund (LSMIF) to expand their viral vector and DNA manufacturing facilities for more than 8,000 sqM. |
| 2022 | Contracts/Agreements | In May, the company entered into an agreement to acquire the Coventry API manufacturing site in the US from Noramco. |
Competitor Comparison
| Key Parameters | Pharmaron Beijing Co Ltd | Sinopharm Group Co Ltd | China Resources Pharmaceutical Group Ltd | CSPC Pharmaceutical Group Ltd | Accela ChemBio Inc |
|---|---|---|---|---|---|
| Headquarters | China | China | Hong Kong | China | United States of America |
| City | Beijing | Shanghai | Hong Kong | Shijiazhuang | San Diego |
| State/Province | Beijing | Shanghai | - | Hebei | California |
| No. of Employees | 19,481 | 115,959 | 72,986 | 23,500 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Boliang Lou, Ph.D. | Chairman; Chief Executive Officer | Executive Board | 2016 | 60 |
| Lou Xiaoqiang | Chief Operating Officer; Director | Executive Board | 2016 | 55 |
| Lou Boliang | Director | Executive Board | 2022 | - |
| Bei Zheng | Director; Executive Vice President | Executive Board | 2016 | 56 |
| Zheng Bei | Director | Executive Board | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward